En la evolución de la hepatopatía crónica y del etilismo puede aparecer como complicación una enfermedad ósea metabólica, Osteoporosis (OP) u Osteomalacia (OM), que en el caso de la cirrosis se ha denominado Osteodistrofia Hepática (ODH). Su etiopatogenia no está del todo aclarada, y se ha dado por muchos autores una gran importancia a...
-
December 10, 2018 (v1)PublicationUploaded on: March 27, 2023
-
September 14, 2020 (v1)Publication
Sunitinib (Su) is a tyrosine kinase inhibitor with antiangiogenic and antineoplastic effects that is recommended therapy for renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Arterial hypertension is one of the adverse effects observed in the treatment with Su. The aim of this work was to deepen our...
Uploaded on: December 5, 2022 -
October 10, 2022 (v1)Publication
La monitorización ambulatoria de la presión arterial (MAPA) ha demostrado la utilidad en la evaluación pronóstica de los pacientes hipertensos con insuficiencia cardíaca (IC) con o sin otras enfermedades cardiovasculares. El objetivo de este estudio consistió en determinar si la MAPA puede identificar a pacientes con IC con un peor...
Uploaded on: March 24, 2023 -
May 2, 2023 (v1)Publication
There are studies that evaluate the association between chronic obstructive pulmonary disease (COPD) and heart failure (HF) but there is little evidence regarding the prognosis of this comorbidity in older patients admitted for acute HF. In addition, little attention has been given to the extracardiac and extrapulmonary symptoms presented by...
Uploaded on: May 4, 2023 -
September 29, 2022 (v1)Publication
Introduction: Heart failure (HF) and cancer are currently the leading causes of death worldwide, with an increasing incidence with age. Little is known about the treatment received and the prognosis of patients with acute HF and a prior cancer diagnosis. Objective: to determine the clinical characteristics, palliative treatment received, and...
Uploaded on: December 2, 2022 -
November 29, 2023 (v1)Publication
Uso de la L-carnitina y sus composiciones, para el tratamiento y la prevención del daño renal. Uso de la L-carnitina o cualquiera de sus sales, profármacos, derivados o análogos, o cualquiera de sus combinaciones, y de sus composiciones alimentarias y farmacéuticas, para la prevención o el tratamiento del daño renal.
Uploaded on: December 3, 2023